{
    "ticker": "CONL",
    "name": "Concordia International Corp.",
    "description": "Concordia International Corp. is a global pharmaceutical company that specializes in the acquisition, in-licensing, and commercialization of innovative and established branded and generic pharmaceuticals. Founded in 2013 and headquartered in Toronto, Canada, Concordia focuses on providing access to high-quality medications across various therapeutic areas, including pain management, dermatology, and infectious diseases. The company operates through a diverse product portfolio and strategic partnerships, enabling it to deliver essential medicines to patients around the world. Concordia aims to enhance the health and well-being of patients while maintaining a commitment to quality and compliance in all its operations. With an experienced management team and a dedication to strategic growth, Concordia seeks to expand its market presence and deliver sustainable value to its stakeholders. The company's mission is to ensure that patients have access to the medications they need, when they need them, while continuously striving to innovate within the pharmaceutical landscape.",
    "industry": [
        "Pharmaceuticals"
    ],
    "headquarters": "Toronto, Ontario, Canada",
    "founded": "2013",
    "website": "https://www.concordiapharma.com",
    "ceo": "Mark Thompson",
    "social_media": {
        "twitter": "https://twitter.com/ConcordiaPharma",
        "linkedin": "https://www.linkedin.com/company/concordia-international-corp/"
    },
    "investor_relations": "https://www.concordiapharma.com/investors",
    "key_executives": [
        {
            "name": "Mark Thompson",
            "position": "CEO"
        },
        {
            "name": "John Smith",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Branded Pharmaceuticals",
            "products": [
                "Pain Relief Medication",
                "Dermatology Products"
            ]
        },
        {
            "category": "Generic Pharmaceuticals",
            "products": [
                "Antibiotics",
                "Cardiovascular Products"
            ]
        }
    ],
    "seo": {
        "meta_title": "Concordia International Corp. | Global Pharmaceutical Provider",
        "meta_description": "Explore Concordia International Corp., a global leader in pharmaceuticals committed to providing high-quality medications across various therapeutic areas.",
        "keywords": [
            "Concordia International",
            "Pharmaceuticals",
            "Branded Drugs",
            "Generic Drugs",
            "Health Care",
            "Medications"
        ]
    },
    "faq": [
        {
            "question": "What does Concordia International Corp. do?",
            "answer": "Concordia International Corp. is a global pharmaceutical company that specializes in acquiring and commercializing branded and generic pharmaceuticals."
        },
        {
            "question": "Who is the CEO of Concordia International?",
            "answer": "Mark Thompson is the CEO of Concordia International Corp."
        },
        {
            "question": "Where is Concordia headquartered?",
            "answer": "Concordia is headquartered in Toronto, Ontario, Canada."
        },
        {
            "question": "What are the main therapeutic areas of Concordia?",
            "answer": "Concordia focuses on pain management, dermatology, and infectious diseases."
        },
        {
            "question": "When was Concordia founded?",
            "answer": "Concordia was founded in 2013."
        }
    ],
    "competitors": [
        "PFE",
        "JNJ",
        "ABT",
        "GILD"
    ],
    "related_stocks": [
        "MRK",
        "BMY",
        "AMGN",
        "SNY"
    ]
}